Literature DB >> 26361116

New cancer therapies and jaw necrosis.

V Patel1, M Kelleher2, C Sproat1, J Kwok1, M McGurk3.   

Abstract

Osteonecrosis of the jaw (ONJ) has a number of causes, the most familiar being radiation or bisphosphonate induced. Various other novel anti-neoplastic and bone-targeting therapies that can also cause jaw necrosis have recently become available. This has led to the suggested acronym MRONJ for medication-related osteonecrosis of the jaw. This article summarises the available information on these drugs and their implications for the dental surgeon.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26361116     DOI： 10.1038/sj.bdj.2015.680

Source DB:  PubMed          Journal:  Br Dent J        ISSN： 0007-0610            Impact factor:   1.626


  60 in total

1.  The conservative management of osteoradionecrosis of the mandible with ultrasound therapy.

Authors:  M Harris
Journal:  Br J Oral Maxillofac Surg       Date:  1992-10       Impact factor: 1.651

Review 2.  Radioimmunotherapy with alpha-emitting nuclides.

Authors:  M R McDevitt; G Sgouros; R D Finn; J L Humm; J G Jurcic; S M Larson; D A Scheinberg
Journal:  Eur J Nucl Med       Date:  1998-09

3.  Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

Authors:  Valentina Guarneri; David Miles; Nicholas Robert; Véronique Diéras; John Glaspy; Ian Smith; Christoph Thomssen; Laura Biganzoli; Tanya Taran; PierFranco Conte
Journal:  Breast Cancer Res Treat       Date:  2010-04-02       Impact factor: 4.872

Review 4.  High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?

Authors:  Øyvind S Bruland; Sten Nilsson; Darrell R Fisher; Roy H Larsen
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

5.  Infectious diseases of the jaws.

Authors:  I Meyer
Journal:  J Oral Surg       Date:  1970-01

6.  Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model.

Authors:  Gjermund Henriksen; Knut Breistøl; Øyvind S Bruland; Øystein Fodstad; Roy H Larsen
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

7.  A new concept in the treatment of osteoradionecrosis.

Authors:  R E Marx
Journal:  J Oral Maxillofac Surg       Date:  1983-06       Impact factor: 1.895

8.  Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.

Authors:  Jeanny B Aragon-Ching; Yang-Min Ning; Clara C Chen; Lea Latham; Jean-Pierre Guadagnini; James L Gulley; Philip M Arlen; John J Wright; Howard Parnes; William D Figg; William L Dahut
Journal:  Cancer Invest       Date:  2009-02       Impact factor: 2.176

9.  Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.

Authors:  C Kollmannsberger; D Soulieres; R Wong; A Scalera; R Gaspo; G Bjarnason
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

10.  Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports.

Authors:  A Agrillo; E Nastro Siniscalchi; A Facchini; F Filiaci; C Ungari
Journal:  Eur Rev Med Pharmacol Sci       Date:  2012-07       Impact factor: 3.507
View more
  7 in total

1.  Photodynamic Therapy as an adjunct in the Treatment of Medication-Related Osteonecrosis of the Jaw: A Case Report.

Authors:  Marcelo Vieira da Costa Almeida; Antonio C Moura; Lúcia Santos; Luciana Gominho; Ully Dias Nascimento Távora Cavalcanti; Kaline Romeiro
Journal:  J Lasers Med Sci       Date:  2021-03-08

Review 2.  Interventions for managing medication-related osteonecrosis of the jaw.

Authors:  Natalie H Beth-Tasdogan; Benjamin Mayer; Heba Hussein; Oliver Zolk; Jens-Uwe Peter
Journal:  Cochrane Database Syst Rev       Date:  2022-07-12

3.  MRONJ risk of adjuvant bisphosphonates in early stage breast cancer.

Authors:  V Patel; J Mansi; S Ghosh; J Kwok; M Burke; D Reilly; N Nizarali; C Sproat; K Chia
Journal:  Br Dent J       Date:  2017-12-15       Impact factor: 1.626

4.  Denosumab - a new medication in the treatment of postmenopausal osteoporosis.

Authors:  Radosław Słopień; Piotr Rynio; Elżbieta Kubala; Ewa Milewska; Blazej Meczekalski
Journal:  Prz Menopauzalny       Date:  2017-10-12

5.  Antiresorptive medication in oncology: the clinical and dental profile of patients in a reference center.

Authors:  Vitor Hugo Candido Ferreira; Aristilia Tahara Kemp; Joana Vendruscolo; Laurindo Moacir Sassi; Juliana Lucena Schussel
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2021-02-28

Review 6.  Interventions for managing medication-related osteonecrosis of the jaw.

Authors:  Natalie H Beth-Tasdogan; Benjamin Mayer; Heba Hussein; Oliver Zolk
Journal:  Cochrane Database Syst Rev       Date:  2017-10-06

7.  Could the Combined Administration of Bone Antiresorptive Drug, Taxanes, and Corticosteroids Worsen Medication Related Osteonecrosis of the Jaws in Cancer Patients?

Authors:  Giacomo Oteri; Giuseppina Campisi; Vera Panzarella; Ilaria Morreale; Riccardo Nucera; Olga Di Fede; Antonio Picone; Antonia Marcianò
Journal:  Biomed Res Int       Date:  2018-05-29       Impact factor: 3.411
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.